The Effect of miR-106b-5p Expression in The Production of iPS-Like Cells from Mice SSCs during The Formation of Teratoma and The Three Embryonic Layers

Document Type : Original Article

Authors

1 Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Anatomical Sciences, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Abstract

Objective: According to the mounting data, microRNAs (miRNAs) may play a key role in reprogramming. miR-106b
is considered as an enhancer in reprogramming efficiency. Based on induced pluripotent stem cells (iPSCs), cell treatments have a huge amount of potential. One of the main concerns about using iPSCs in therapeutic settings is the possibility of tumor formation. It is hypothesized that a procedure that can reprogram cells with less genetic manipulation reduces the possibility of tumorigenicity.
Materials and Methods: In this experimental study, miR-106b-5p transduced by pLV-miRNA vector into mice isolated spermatogonial stem cells (SSCs) to achieve iPS-like cells. Then the transduced cells were cultured in specific conditions to study the formation of three germ layers. The tumorigenicity of these iPS-like cells was investigated by transplantation into male BALB/C mice.
Results: We show that SSCs can be successfully reprogrammed into induced iPS-like cells by pLV-miRNA vector to transduce the hsa-mir-106b-5p into SSCs and generating osteogenic, neural and hepatoblast lineage cells in vitro as a result of pluripotency. Although these iPS-like cells are pluripotent, they cannot form palpable tumors in vivo.
Conclusion: These results demonstrate that infection of hsa-mir-106b-5p into SSCs can reprogram them into iPSCs
and advanced germ cell lineages without tumorigenicity. Also, a novel approach for studying the generation of iPSCs
and the application of iPS or iPS-like cells in regenerative medicine is presented.

Keywords

References

1. Liu G, David BT, Trawczynski M, Fessler RG. Advances in pluripotent stem cells history, mechanisms, technologies, and applications. Stem Cell Rev Rep. 2020; 16(1): 3-32.
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4): 663-676.
3. Pires CF, Rosa FF, Kurochkin I, Pereira CF. Understanding and modulating immunity with cell reprogramming. Front Immunol. 2019; 10: 2809.
4. Corbett JL,Duncan SA. iPSC-derived hepatocytes as a platform for disease modeling and drug discovery. Front Med. 2019; 6: 265.
5. Lim SJ, Ho SC, Mok PL, Tan KL, Ong AH, Gan SC. Induced pluripotent stem cells from human hair follicle keratinocytes as a potential source for in vitro hair follicle cloning. PeerJ. 2016; 4: e2695.
6. Miller JD, Schlaeger TM. Generation of induced pluripotent stem cell lines from human fibroblasts via retroviral gene transfer. Methods Mol Biol. 2011; 767: 55-65.
7. Aponte PM. Spermatogonial stem cells: Current biotechnological advances in reproduction and regenerative medicine. World J Stem Cells. 2015; 7(4): 669.
8. Dym M, Kokkinaki M, He Z. Spermatogonial stem cells: mouse and human comparisons. Birth Defects Research (Part C). 2009; 87(1): 27-34.
9. Lee SW, Wu G, Choi NY, Lee HJ, Bang JS, Lee Y, et al. Self-reprogramming of spermatogonial stem cells into pluripotent stem cells without microenvironment of feeder cells. Mol Cells. 2018; 41(7): 631.
10. Wienholds E, Plasterk R H. MicroRNA function in animal development. FEBS Lett. 2005; 579 (26): 5911-5922.
11. Doeleman MJH, Feyen DAM, de Veij Mestdagh CF, Sluijter JPG. Cardiac regeneration and microRNAs: regulators of pluripotency, reprogramming, and cardiovascular lineage commitment. In: Madonna R, editor. Stem Cells and cardiac regeneration. 1st ed. Cham: Springer; 2016; 79-109.
12. Li Z, Yang CS, Nakashima K, Rana TM. Small RNA-mediated regulation of iPS cell generation. EMBO J. 2011; 30(5): 823-834.
13. Mehlich D, Garbicz F,Włodarski PK. The emerging roles of the polycistronic miR-106b- 25 cluster in cancer–a comprehensive review. Biomed Pharmacother. 2018; 107: 1183-1195.
14. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M, Real PJ, Mácia A, et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells. 2010; 28(9): 1568-1570.
15. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells. 2009; 27(5): 1050-1056.
16. Hasani Fard AH, Mohseni Kouchesfehani H, Jalali H. Investigation of cholestasis-related changes in characteristics of spermatogonial stem cells in testis tissue of male Wistar rats. Andrologia. 2020; 52(9): e13660.
17. Velasco V, Shariati SA, Esfandyarpour R. Microtechnology-based methods for organoid models. Microsyst Nanoeng. 2020; 6(1): 1-13.
18. Bakhshalizadeh S, Esmaeili F, Houshmand F, Ebrahimi Hafshejani M, Ghasemi S. Neuronal differentiation of GFP expressing P19 embryonal carcinoma cells by deprenyl, an antiparkinson drug. J Shahrekord Univ Med Sci. 2014; 16.
19. Mazaheri Z, Movahedin M, Rahbarizadeh F, Amanpour S. Different doses of bone morphogenetic protein 4 promote the expression of early germ cell-specific gene in bone marrow mesenchymal stem cells. In Vitro Cell Dev Biol Anim. 2011; 47(8): 521-525.
20. Fekri Aval S, Zarghami N, Mohammadi SA, Nouri M. Isolation of mesenchymal stem cells from human adipose tissue and comparison of miRNA-16 and miRNA-125b expression before and after differentiation into adipocytes and liver cells. Presented for the Ph.D., Tabriz. Tabriz University of Medical Sciences. 2017.
21. Ahmadi A, Moghadasali R, Ezzatizadeh V, Taghizadeh Z, Nassiri SM, Asghari-Vostikolaee MH, et al. Transplantation of mouse induced pluripotent stem cell-derived podocytes in a mouse model of
membranous nephropathy attenuates proteinuria. Sci Rep. 2019; 9(1): 1-13.
22. Costoya JA, Hobbs RM, Barna M, Cattoretti G, Manova K, Sukhwani M, et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet. 2004; 36(6): 653-659.
23. Locher H, de Rooij KE, de Groot JC, van Doorn R, Gruis NA, Löwik CW, et al. Class III β-tubulin, a novel biomarker in the human melanocyte lineage. Differentiation. 2013; 85(4-5): 173-181.
24. Lansley SM, Searles RG, Hoi A, Thomas C, Moneta H, Herrick SE, et al. Mesothelial cell differentiation into osteoblast and adipocytelike cells. J Cell Mol Med. 2011; 15(10): 2095-2105.
25. Freyer N, Knöspel F, Strahl N, Amini L, Schrade P, Bachmann S, et al. Hepatic differentiation of human induced pluripotent stem cells in a perfused three-dimensional multicompartment bioreactor. Biores Open Access. 2016; 5(1): 235-248.
26. Pellicano R, Caviglia GP, Ribaldone DG, Altruda F, Fagoonee S. Induced pluripotent stem cells from spermatogonial stem cells: potential applications. In: Birbrair A, editor. Cell sources for iPSCs. 1st ed. London: Academic Press; 2021; 15-35.
27. Yang M, Deng B, Geng L, Li L, Wu X. Pluripotency factor NANOG promotes germ cell maintenance in vitro without triggering dedifferentiation of spermatogonial stem cells. Theriogenology. 2020; 148: 68-75.
28. Kanatsu-Shinohara M, Inoue K, Lee J, Yoshimoto M, Ogonuki N, Miki H, et al. Generation of pluripotent stem cells from neonatal mouse testis. Cell. 2004; 119(7): 1001-1012.
29. Chen Z, Hong F, Wang Z, Hao D,Yang H. Spermatogonial stem cells are a promising and pluripotent cell source for regenerative medicine. Am J Transl Res. 2020; 12(11): 7048.
30. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008; 26(1): 101-106.
31. Anokye-Danso F, Snitow M, Morrisey EE. How microRNAs facilitate eprogramming to pluripotency. J Cell Sci. 2012; 125(18): 4179-4787.
32. Greve T S, Judson RL, Blelloch R. microRNA control of mouse and human pluripotent stem cell behavior. Annu Rev Cell Dev Biol. 2013; 29: 213-239.
33. Leonardo TR, Schultheisz HL, Loring JF, Laurent LC. The functions of microRNAs in pluripotency and reprogramming. Nat Cell Biol. 2012; 14(11): 1114-1121.
34. Lüningschrör P, Hauser S, Kaltschmidt B, Kaltschmidt C. MicroRNAs in pluripotency, reprogramming and cell fate induction. Biochim Biophys Acta Mol Cell Res. 2013; 1833(8): 1894-1903.
35. Lin SL, Chang DC, Lin CH, Ying SY, Leu D, Wu DT. Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Res. 2011; 39(3): 1054-1065.
36. Nguyen PNN, Choo KB, Huang CJ, Sugii S, Cheong SK, Kamarul T. miR-524-5p of the primate-specific C19MC miRNA cluster targets TP53IPN1-and EMT-associated genes to regulate cellular reprogramming. Stem Cell Res Ther. 2017; 8(1): 1-15.
37. Tong MH, Mitchell DA, McGowan SD, Evanoff R, Griswold MD. Two miRNA clusters, Mir-17-92 (Mirc1) and Mir-106b-25 (Mirc3), are involved in the regulation of spermatogonial differentiation in mice. Biol Reprod. 2012; 86(3): 72.
38. Guan K, Nayernia K, Maier LS, Wagner S, Dressel R, Lee JH, et al. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature. 2006; 440(7088): 1199-1203.
39. Lim JJ, Kim HJ, Kim KS, Hong JY, Lee DR. In vitro culture-induced pluripotency of human spermatogonial stem cells. Biomed Res Int. 2013; 2013.
40. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013; 19(8): 998-1004.

Files

Cited by

Share

How to cite

Statistics